Her2-Positive Biliary Tract Cancer: New Developments And Future Directions

HER2-Positive Biliary Tract Cancer: New Developments and Future Directions

Future developments in immunotherapy for treatment of biliary tract cancer

Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer

Future directions in bile duct cancers

ASCO 2024 Top 5 Zanidatamab Phase 2 HER2+ Questions on Biliary Tract Cancer

Future directions in gastrointestinal cancer

Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?

Biomarker directed therapies in biliary tract cancers

Dr Harding on the FDA Approval of Zanidatamab for HER2+ Biliary Tract Cancer

Dr Pant on the Utility of Zanidatamab in Previously Treated HER2+ Biliary Tract Cancer

CCF Webinar: A clinical trial for a potential new tHER2apy for biliary tract cancers

Cholangiocarcinoma Foundation

SGNTUC-019: tucatinib + trastuzumab for previously treated HER2+ metastatic biliary tract cancer

Final results from the phase 2 SUMMIT basket trial: targeting HER2+ advanced BTCs with neratinib

Advances in treating biliary tract cancers with targeted therapies

Webinar: HER2-targeted therapies in CCA

Cholangiocarcinoma Foundation

Biliary Tract and Pancreatic Cancer: HER2-Targeted ADCs for Gastrointestinal Cancers

Evolution of HER2-Targeted Therapy in Biliary Tract Cancer

AACR 2023 highlights on advances in the treatment of biliary tract cancer with Robin Katie Kelley

European Society for Medical Oncology (ESMO)

The significance of tucatinib + trastuzumab as a chemotherapy-free option for HER2+ metastatic BTC

AC21 - Shubham Pant: Targeting HER2 in Biliary Tract Cancers

Cholangiocarcinoma Foundation